Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine
Sign Up to like & getrecommendations! Published in 2022 at "Toxins"
DOI: 10.3390/toxins14080529
Abstract: OnabotulinumtoxinA, targeting the CGRP machinery, has been approved for the last two decades for chronic migraine prevention. The recently approved monoclonal antibodies (mAbs) directed towards the calcitonin gene-related peptide (CGRP) pathway open a new age… read more here.
Keywords: mabs onabotulinumtoxina; cgrp mabs; chronic migraine; evidence ... See more keywords